Sera Prognostics Yönetim

Yönetim kriter kontrolleri 2/4

Sera Prognostics CEO'su Zhenya Lindgardt, May2023 tarihinde atandı, in görev süresi 1.5 yıldır. in toplam yıllık tazminatı $ 2.44M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.4% maaş ve 87.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.39% ine doğrudan sahiptir ve bu hisseler $ 851.73K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.1 yıl ve 8.3 yıldır.

Anahtar bilgiler

Zhenya Lindgardt

İcra Kurulu Başkanı

US$2.4m

Toplam tazminat

CEO maaş yüzdesi	12.4%
CEO görev süresi	1.5yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	3.1yrs
Yönetim Kurulu ortalama görev süresi	8.3yrs

Son yönetim güncellemeleri

Recent updates

Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?

Oct 03

We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth

Jun 15

We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate

Feb 16

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Nov 03

A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening

Aug 10

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Jul 21

Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation

Apr 06

We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely

Dec 15

CEO Tazminat Analizi

Zhenya Lindgardt'un ücretlendirmesi Sera Prognostics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$32m
Jun 30 2024	n/a	n/a	-US$32m
Mar 31 2024	n/a	n/a	-US$34m
Dec 31 2023	US$2m	US$303k	-US$36m
Sep 30 2023	n/a	n/a	-US$38m
Jun 30 2023	n/a	n/a	-US$42m
Mar 31 2023	n/a	n/a	-US$43m
Dec 31 2022	US$158k	n/a	-US$44m
Sep 30 2022	n/a	n/a	-US$47m
Jun 30 2022	n/a	n/a	-US$46m
Mar 31 2022	n/a	n/a	-US$41m
Dec 31 2021	US$245k	n/a	-US$35m

Tazminat ve Piyasa: Zhenya 'nin toplam tazminatı ($USD 2.44M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.46M ).

Tazminat ve Kazançlar: Zhenya şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Zhenya Lindgardt (50 yo)

1.5yrs

Görev süresi

US$2,435,920

Tazminat

Ms. Evguenia Lindgardt, also known as Zhenya, MBA, has been a Director of Sera Prognostics, Inc since November 2021 and serves as its Chief Executive Officer since May 2023 and serves as its President sinc...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Evguenia Lindgardt	President	1.5yrs	US$2.44m	0.39% $ 851.7k
Austin Aerts	Chief Financial Officer	1.4yrs	US$1.04m	0.20% $ 432.3k
John Boniface	Chief Scientific Officer	13yrs	US$871.96k	0.14% $ 296.5k
Gregory Critchfield	Executive Director	1.5yrs	US$1.51m	2.23% $ 4.9m
Robert Harrison	Chief Information Officer	3.7yrs	US$1.99m	0.14% $ 303.8k
Benjamin Jackson	General Counsel	3.6yrs	US$1.71m	0.16% $ 351.0k
Paul Kearney	Chief Data Officer	3.1yrs	Veri yok	0.30% $ 659.4k

3.1yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: SERA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Evguenia Lindgardt	President	3yrs	US$2.44m	0.39% $ 851.7k
Gregory Critchfield	Executive Director	no data	US$1.51m	2.23% $ 4.9m
Joshua Phillips	Independent Director	13yrs	US$175.00k	0.11% $ 235.6k
Sandra A. Lawrence	Independent Director	3yrs	US$162.50k	0% $ 0
Ryan Trimble	Independent Director	13.7yrs	US$162.50k	0.30% $ 647.6k
Robert Getzenberg	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Kim Kamdar	Independent Chairman	13yrs	US$192.58k	0.020% $ 42.7k
Amos Madanes	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
C. Peterson	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
D. Branch	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Silver	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Marcus Wilson	Independent Director	3.7yrs	Veri yok	Veri yok

8.3yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SERA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.3 yıldır).

Sera Prognostics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chief Data Officer recently sold US$86k worth of stock

Sera Prognostics, Inc., Annual General Meeting, Jun 06, 2024

Chief Scientific Officer notifies of intention to sell stock

President recently sold US$364k worth of stock

President recently sold US$225k worth of stock

Independent Chairman notifies of intention to sell stock

Recent updates

Sera Prognostics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Sera Prognostics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Sera Prognostics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

We're Not Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn

Sera Prognostics Inc. Announces Publication of Positive AVERT Trial Results in the International Peer-Reviewed Journal, Diagnostics

Chief Data Officer recently sold US$86k worth of stock

First quarter 2024 earnings released: US$0.25 loss per share (vs US$0.34 loss in 1Q 2023)

Sera Prognostics, Inc. to Report Q1, 2024 Results on May 08, 2024

Sera Prognostics, Inc., Annual General Meeting, Jun 06, 2024

Chief Scientific Officer notifies of intention to sell stock

President recently sold US$364k worth of stock

Sera Prognostics' PreTRM: A Speculative Buy In Women's Health

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

No longer forecast to breakeven

Sera Prognostics, Inc. to Report Q4, 2023 Results on Mar 20, 2024

President recently sold US$225k worth of stock

Sera Prognostics: The Pregnancy Company On A Hot Streak

Independent Chairman notifies of intention to sell stock

General Counsel recently sold US$52k worth of stock

New major risk - Share price stability

Sera Prognostics Inc. Announces Preliminary Efficacy Met in Pivotal Prime Study Interim Look - Enrollment to Stop Due to Success

Consensus revenue estimates decrease by 14%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sera Prognostics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates decrease by 55%, EPS upgraded

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Sera Prognostics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Market cap size

We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth

Sera Prognostics, Inc. Announces Resignation of Nadia Altomare from the Position of Chief Commercial Officer of the Company, Effective as of June 9, 2023

Sera Prognostics, Inc. Announces Board Changes

First quarter 2023 earnings: EPS exceeds analyst expectations

Full year 2022 earnings: Revenues miss analyst expectations

Sera Prognostics, Inc. Announces Positive Top-Line Data from AVERT PRETERM TRIAL

We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate

Sera Prognostics, Inc. Announces Publication of Data Predicting Clinical Utility and Cost Effectiveness of the Pretrm® Test-And-Treat Strategy Across Diverse Populations

Insufficient new directors

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Sera Prognostics, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Price target decreased to US$7.00

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening

Sera Prognostics, Inc. to Report Q2, 2022 Results on Aug 10, 2022

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Chief Scientific Officer notifies of intention to sell stock

Sera Prognostics Appoints Jane Barlow to Nominating and Governance Committee

Sera Prognostics, Inc.(NasdaqGM:SERA) dropped from Russell 2500 Value Index

Sera Prognostics, Inc. Announces Publication of Data Demonstrating Improved Performance of its PreTRM Test with More Precise Gestational Age

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Sera Prognostics, Inc. to Report Q1, 2022 Results on May 10, 2022

Insufficient new directors

Sera Prognostics, Inc., Annual General Meeting, Jun 03, 2022

Sera Prognostics, Inc Appoints Jane F. Barlow as Director to the Board to Serve as Class I Director

Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Chief Scientific Officer exercised options to buy US$282k worth of stock.

Insufficient new directors

We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely

Sera Prognostics Inc. Announces Pricing for PreTRM® Test, the Only Broadly Validated Blood Test to Assess Risk of Preterm Birth

Third quarter 2021 earnings released: US$0.39 loss per share

Sera Prognostics, Inc. Announces Publication of Health Economic Analysis Supporting Pretrm Test-And-Treat Strategy to Improve Maternal and Infant Health

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat